por
Gus Iversen, Editor in Chief | June 23, 2025
Ratio Therapeutics has signed a long-term supply agreement with Nusano to secure commercial-scale access to several key medical isotopes used in cancer imaging and treatment.
Under the agreement, the Boston-based pharmaceutical company will receive a steady supply of copper-64 (Cu-64) for PET imaging diagnostics, along with lutetium-177 (Lu-177) and actinium-225 (Ac-225) for therapeutic use. The isotopes will be supplied by Nusano, a West Valley City, Utah-based radioisotope producer with a proprietary platform capable of generating over 40 isotopes for medical and industrial applications.
Jack Hoppin, chairman and CEO of Ratio Therapeutics, said the deal addresses persistent supply constraints that have hindered broader clinical use of Cu-64 and other isotopes.
Ad Statistics
Times Displayed: 40425
Times Visited: 1116 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
“Limited supply and high costs of Cu-64 have put significant constraints on its clinical use,” Hoppin said. “By accessing Nusano’s production capabilities, we’re removing a critical bottleneck and enabling broader adoption across the field.”
Ratio is currently advancing a pipeline of targeted radiotherapeutics, including a fibroblast activation protein (FAP) — targeted therapy for soft tissue sarcoma expected to enter clinical trials this year. The company’s manufacturing facility in Utah is located close to Nusano’s site, which is expected to simplify logistics and support future scale-up.
Nusano CEO Chris Lowe described the partnership as a strategic step toward improving access to radiopharmaceutical tools for cancer care.
“We’re seeing strong, sustained growth in the use of Cu-64 for PET imaging, and rapidly increasing interest in isotopes such as Ac-225 for targeted cancer treatments,” Lowe said. “By collaborating with forward-thinking radiopharmaceutical companies like Ratio, we’re working to meet current clinical needs and support the development of next-generation radiopharmaceuticals.”
The companies say the supply agreement supports their shared goal of expanding innovation in radiopharmaceuticals amid rising demand for diagnostic and therapeutic isotopes.
